COA566

ApprovedCompleted
0 views this week 0 watching Active
Interest: 43/100
43
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Malaria

Conditions

Malaria

Trial Timeline

Nov 1, 2010 → Jul 1, 2012

About COA566

COA566 is a approved stage product being developed by Novartis for Malaria. The current trial status is completed. This product is registered under clinical trial identifier NCT01256658. Target conditions include Malaria.

What happened to similar drugs?

10 of 18 similar drugs in Malaria were approved

Approved (10) Terminated (1) Active (8)

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01256658ApprovedCompleted